The new entity, NITO Renewable Energy, Inc., to hold all current and future solar operations of the Company Neve Yarak, Israel, March 03, 2025 (GLOBE NEWSWIRE) — N2OFF, Inc. (NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in sustainable solutions for energy and innovation for agri- tech, announced today the establishment of a new wholly-owned US subsidiary, NITO Renewable Energy, Inc., that is registered in Nevada. The new entity will focus and consolidate the Company’s current and future Solar PV activities. The Company is currently invested in 3 projects in two countries in Europe. Germany: The joint venture is developing a 111 MWp solar photovoltaic (PV) project in Melz, Germany. This project has secured municipal approval and an indicative grid connection solution from a regional energy service...

Program provides up to $150,000 to support up-and-coming filmmakers and drive a new generation of talent Submissions open March 10, Five winners selected by award-winning creators David Lowery, Charlotte Wells, Sean Wang, Savanah Leaf and Adam Bricker, ASC. NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) — Vimeo, the world’s most innovative video experience platform for creators and enterprises, today announced the launch of the first-ever “Vimeo Short Film Grant presented by Nikon | RED.” This initiative will empower emerging filmmakers to bring their creative visions to life with the support and mentorship of industry visionaries, class-leading equipment, and distribution to Vimeo’s vast global audience. The grant will award five filmmakers with $30,000 each in funding to produce a short film, along with one-on-one mentorship...

Conference Call and Webcast Scheduled for March 13, 2025 at 2:00 p.m. PT/5:00 p.m. ETSOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the fourth quarter and full year 2024 financial results and provide a business update on March 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. Listen-Only WebcastThe listen-only webcast will be made available on the Company’s website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company’s...

REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2024 financial results will be released after market close on Monday, March 10, 2025. Starting at 5:00 p.m. ET on March 10, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. Conference Call Information When: Monday, March 10, 2025, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.media-server.com/register/BIddb737c625d842e0867fa22a43106197 Webcast: https://edge.media-server.com/mmc/p/3dwbidfe The press release with the fourth...

Empowering Mobile Operators and Service Providers toRapidly Launch and Monetize Consumer Cloud Services BRIDGEWATER, N.J., March 03, 2025 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss”) (NASDAQ: SNCR), a global leader in personal cloud solutions, today introduced Capsyl Cloud™, a new turn-key personal cloud platform designed for mobile operators and broadband service providers worldwide. Capsyl Cloud expands Synchronoss’s cloud portfolio, enabling service providers to launch secure, scalable, and revenue-generating personal cloud services with minimal deployment time. Synchronoss will showcase live demonstrations of Capsyl Cloud at MWC Barcelona in Executive Suite [3A19EX], providing a first-hand look at how operators can rapidly deploy and monetize branded cloud services. Capsyl Cloud is a secure, cross-platform...

Patent Strengthens Nexalin’s Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids, Alcohol, Cocaine and Methamphetamine HOUSTON, TX, March 03, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled “Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder (OUD) and Substance Use Disorder (SUD).” This newly allowed patent covers Nexalin’s proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology, a non-invasive, drug-free...

Interim President & CEO Jim Janik Returning to Role as Chairman of the Board of Directors MILWAUKEE, March 03, 2025 (GLOBE NEWSWIRE) — Douglas Dynamics, Inc. (NYSE: PLOW), North America’s premier manufacturer and upfitter of work truck attachments and equipment, today announced the Board of Directors has appointed Mark Van Genderen as President and Chief Executive Officer (CEO), effective immediately. He will also join the Board of Directors effective immediately. Mr. Van Genderen has been with the company for five years, and most recently served as Chief Operating Officer and President of Work Truck Attachments. He succeeds Interim President & CEO, James (Jim) L. Janik, who will return to his former role as Chairman of the Board of Directors. “Over the past five years, Mark has developed a deep understanding of...

– CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin –– Phase 1 study in healthy volunteers ongoing – HAMPTON, N.J., March 03, 2025 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive preclinical data from CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis—thymic stromal lymphopoietin (TSLP) and mast cell depletion via stem cell factor (SCF) starvation. The data demonstrate that CDX-622 neutralizes both SCF and TSLP, reducing tissue mast cells and inhibiting Type 2 inflammatory responses, supporting its potential to improve clinical activity over single target inhibition in inflammatory diseases and fibrotic disorders. The data were presented by Diego Alvarado, PhD,...

GREENWICH, Conn., March 03, 2025 (GLOBE NEWSWIRE) — Gabelli Funds is hosting its 16th Annual Specialty Chemicals Symposium taking place at The Harvard Club in New York, NY on Thursday, March 20, 2025.  The symposium will draw a variety of companies, with a focus on pricing power, margin recovery, interest rates, inventory stabilization, global trade policy, demand trends, and the M&A environment.  Attendees will also have the opportunity to meet with managements in a one-on-one setting. Agenda:8:20am Opening Remarks Rosemarie Morbelli, CFA Gabelli Funds    Wayne Pinsent, CFA Gabelli Funds     8:30 Cabot Corporation (NYSE: CBT)* To Be Confirmed          9:00 Arq, Inc. (NASDAQ: ARQ) Bob Rasmus, President & CEO          9:30 BASF Corporation (XETRA: BAS.DE) Alex Koehler, Investor Relations          10:00 American...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s fourth quarter 2024 financial results on Monday, March 10, 2025, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus infection,...